Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses

Published:2016-10-11 Issue:11 Volume:12 Page:1381-1392
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Bose Prithviraj¹,Gandhi Varsha V.¹²,Keating Michael J.¹

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

National Cancer Institute

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2016.1239717

Reference102 articles.

1. SEER stat fact sheets: Chronic lymphocytic leukemia (CLL) [Internet]. 2016 [cited2016 May 17]. Available from: http://seer.cancer.gov/statfacts/html/clyl.html

2. The B-cell receptor signaling pathway as a therapeutic target in CLL

3. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

4. Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician

5. Initial treatment of CLL: integrating biology and functional status

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib-Induced Ventricular Electrical Storm Successfully Managed with Veno-Arterial ECMO and Intralipid Administration: A Rare Case Report;Annals of Cardiac Anaesthesia;2024-08-28

2. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

3. Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-04-08

4. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study;European Journal of Haematology;2024-02-11

5. Quality by design endorsed fabrication of Ibrutinib-loaded human serum albumin nanoparticles for the management of leukemia;European Journal of Pharmaceutics and Biopharmaceutics;2023-09